Wall Street Associates’s Acceleron Pharma XLRN Stock Holding History

Wall Street Associates’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,400	Closed	-$232K	–	218
2016 Q3	$232K	Hold	6,400	–	–	0.08%	213
2016 Q2	$217K	Buy	+6,400	New	+$208K	0.09%	209
2016 Q1	–	Sell	-6,400	Closed	-$312K	–	284
2015 Q4	$312K	Buy	+6,400	New	+$230K	0.09%	271
2015 Q3	–	Sell	-76,000	Closed	-$2.4M	–	355
2015 Q2	$2.4M	Sell	76,000 -3,000	-4%	-$96.8K	0.23%	116
2015 Q1	$3.01M	Sell	79,000 -3,700	-4%	-$147K	0.28%	108
2014 Q4	$3.22M	Sell	82,700 -500	-0.6%	-$17.4K	0.31%	102
2014 Q3	$2.52M	Sell	83,200 -9,900	-11%	-$279K	0.26%	116
2014 Q2	$3.16M	Buy	93,100 +300	+0.3%	+$10K	0.27%	121
2014 Q1	$3.2M	Sell	92,800 -1,000	-1%	-$45.1K	0.26%	127
2013 Q4	$3.71M	Buy	93,800 +6,300	+7%	+$152K	0.3%	117
2013 Q3	$1.95M	Buy	+87,500	New	+$1.89M	0.18%	164

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Wall Street Associates's XLRN Position: Q4 2016 in Review

Wall Street Associates sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 6,400 shares — an estimated $232K sold.

Wall Street Associates first reported a position in XLRN in Q3 2013 and held it in 11 quarters. The position peaked at $3.71M in Q4 2013. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

Wall Street Associates reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
Wall Street Associates sold 6,400 Acceleron Pharma shares in Q4 2016, an estimated $232K.
Wall Street Associates first reported a position in Acceleron Pharma in Q3 2013 and held it in 11 quarters.
Wall Street Associates's Acceleron Pharma position peaked at $3.71M in Q4 2013.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.